QNRX - CONSENSUS CO - Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) relies on outsourcing research through a pool of independent CROs, which optimizes expenses and eliminates operational risks. High barriers to entry and the exclusivity of orphan rights create a robust moat against competitors in the rare dermatosis niche. The current metric stands at 23.69. The securities price action shown below demonstrates the impact of patents and the success of the QRX003 drug on the company's investment attractiveness.

The consensus forecast represents an aggregated target share price from leading investment houses, reflecting average market expectations for the asset's fair value. By tracking changes in the composite target for the stock, an investor can assess the resilience of Quoin Pharmaceuticals (QNRX) against the expansion of biotech behemoths into the orphan dermatological drug niche, distinguishing a temporary correction from a fundamental devaluation of the business amid fierce industry competition.